Is NCT06926595 recruiting in Hershey, PA?

Yes, NCT06926595 is currently recruiting participants at its Hershey, PA location. This graft-versus-host disease (gvhd) clinical trial is actively enrolling qualified participants.

How do I join the graft-versus-host disease (gvhd) clinical trial in Hershey?

To join this clinical trial in Hershey, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Hershey clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Graft-versus-Host Disease (GVHD) Clinical Trial in Hershey, PA

About This Graft-versus-Host Disease (GVHD) Study in Hershey

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing allogeneic stem cell transplantation following reduced-intensity or non-myeloablative conditioning. The study will focus on matched sibling, matched unrelated, and haploidentical peripheral blood stem cell donors. The primary endpoint is 1-year GVHD-Free Relapse-Free Survival (GRFS). The study seeks to determine if low-dose PTCy offers similar outcomes as higher doses, with potentially reduced toxicity.

Sponsor: Milton S. Hershey Medical Center

Who Can Participate

Inclusion Criteria

Age 18 or older at the time of study enrollment.

Patients with acute leukemia (acute myeloid leukemia, acute lymphoblastic leukemia, mixed phenotype acute leukemia) or chronic myeloid leukemia with no circulating blasts and less than 5% blasts in the bone marrow. Flow cytometric, polymerase chain reaction (PCR) or next generation sequencing (NGS) detected measurable residual disease is permitted.

Patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia with no circulating blasts and less than 10% blasts in the bone marrow (exception allowed due to lack of difference in outcomes with \<5% vs 5-10% blasts in this disease).

Patients with secondary acute myeloid leukemia progressing from pre-existing myelodysplastic syndrome, myeloproliferative disease (MPN), or MDS/MPN overlap syndrome.

Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who are indicated for allogeneic stem cell transplantation.

Patients with lymphoma who are indicated for allogeneic stem cell transplantation, including follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma (including primary mediastinal B cell lymphoma), mantle cell lymphoma, peripheral T cell lymphomas, and Richter's transformation.

Planned reduced intensity or non-myeloablative conditioning regimen.

Patients must have a related or unrelated peripheral blood stem cell donor as follows: Sibling donor must be at least haploidentical using high resolution DNA-based HLA typing. Children or parent donor must be at least haploidentical using high resolution DNA-based HLA typing. Children donors must be at least 18 years of age at the time of evaluation. Unrelated donors must be a 7/8 or 8/8 match at HLA-A, B, C, and DRB1 at high resolution using DNA based typing.

Cardiac function: must demonstrate at ejection fraction of at least 40%.

Pulmonary function: must have FEV1 of at least 50% predicted, and DLCO corrected for hemoglobin of at least 40% predicted.

Karnofsky performance status at least 70%.

Women of childbearing potential (WOCP), defined as not surgically sterile (hysterectomy, tubal ligation, or oophorectomy) or at least 1 year postmenopausal, must have a negative serum pregnancy test before conditioning regimen.

Female patients (unless post-menopausal or surgically sterilized) must agree to practice two effective methods of contraception simultaneously or agree to completely abstain from heterosexual intercourse from the time of signing informed consent through 12 months post-transplant.

Male patients (even if surgically sterilized) who are partners of women of childbearing potential must agree to practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant.

Exclusion Criteria

Prior allogeneic stem cell transplant.

Active central nervous system (CNS) involvement by malignant cells.

Uncontrolled bacterial, viral, or fungal infections (currently taking medication with progression or no clinical improvement).

Seropositive for human immunodeficiency virus (HIV) with detectable viral load, hepatitis B virus (HBV) or hepatitis C virus (HCV) with detectable viral load. Hepatitis B surface antibody positive due to vaccination or natural immunity are permitted. Patients previously treated for HCV and considered to be in sustained virologic remission (SVR) are allowed.

Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III-IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.

Pregnant or lactating female patients (unless feeding via formula). Women of childbearing potential (WOCBP) are required to have a negative serum or urine pregnancy test prior to conditioning regimen.

Serious medical or psychiatric illness likely to interfere with participation in the study.

Use of investigational agents.

Haploidentical related recipient who are positive for DSA ≥ 5000 MFI by solid phase microarray method (Luminex).

Any patient with steroid dose more than 10 mg/day within a week of registration.

Autoimmune disorder requiring any active immunosuppression therapy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Hershey?

Yes, this clinical trial (NCT06926595) has an active research site in Hershey, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Graft-versus-Host Disease (GVHD) Treatment Options in Hershey, PA

If you're searching for graft-versus-host disease (gvhd) treatment options in Hershey, PA, this clinical trial (NCT06926595) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Hershey research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced graft-versus-host disease (gvhd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all graft-versus-host disease (gvhd) clinical trials near you to find additional studies recruiting in your area.

Graft-versus-Host Disease (GVHD) Clinical Trial in Hershey, PA

Expert Care in Hershey

IRB Approved

No-Cost Care

Apply for This Hershey Location

Why Participate?

Simple Process